← Back to Search

Psychedelic

Psilocybin for OCD

Phase < 1
Recruiting
Led By David B Yaden, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month post session 2
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if magic mushrooms are safe & effective for people with OCD. A proof of concept for larger trials to come.

Who is the study for?
This trial is for adults with Obsessive Compulsive Disorder (OCD) who have tried treatment before. Participants should not have used hallucinogens often, be at low risk of suicide, and agree to avoid certain medications and substances before sessions. Women must use effective birth control if applicable.
What is being tested?
The study tests the safety and potential effectiveness of psilocybin as a treatment for OCD. It's an early-stage trial to see if larger studies are warranted, focusing on how this intervention might affect cognitive processes and brain function in OCD patients.
What are the potential side effects?
While not explicitly listed here, psilocybin can cause psychological effects like altered perception, mood changes, disorientation or confusion which typically resolve after the drug wears off but can be distressing.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month post session 2
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month post session 2 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mental Depression
Change in The Yale Brown Obsessive Compulsive Scale (Y-BOCS) score
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
+1 more

Side effects data

From 2021 Phase 2 trial • 95 Patients • NCT02061293
9%
Nausea
7%
Pain
7%
Viral upper resp. tract infection
7%
Back pain
7%
Bronchitis
4%
Diarrhea
4%
Influenza
4%
Headache
4%
Sinus headache
4%
Depressed mood
4%
Depression
4%
Insomnia
4%
Suicidal Ideation
4%
Lower resp. tract congestion
4%
Oropharyngeal pain
4%
Alcohol withdrawal syndrome
2%
Migraine
2%
Thrombocytosis
2%
Constipation
2%
Vomiting
2%
Oedema
2%
Peripheral swelling
2%
Pyrexia
2%
Dermatitis contact
2%
Bronchitis bacterial
2%
Eye infection
2%
Fungal infection
2%
Traumatic lung injury
2%
Hyponatremia
2%
Arthralgia
2%
Musculoskeletal pain
2%
Pain in extremity
2%
Malignant melanoma
2%
Dizziness
2%
Hypoesthesia
2%
Sedation
2%
Anger
2%
Anxiety
2%
Restlessness
2%
Cough
2%
Rhinorrhea
2%
Sinus congestion
2%
Sexual abuse
2%
Endodontic procedure
2%
Mallory-Weiss Syndrom
2%
Anemia
2%
Influenza like Illness
2%
Gingivitis
2%
Arthoscopic surgery
100%
80%
60%
40%
20%
0%
Study treatment Arm
Diphenhydramine
Psilocybin

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Immediate PsilocybinExperimental Treatment1 Intervention
This arm will receive two sessions of psilocybin first (20mg in first session and then, if well tolerated, 30mg).
Group II: Delayed PsilocybinActive Control1 Intervention
Waitlist control. This arm will receive psilocybin after the waiting period is over (20mg in first session and then, if well tolerated, 30mg).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Psilocybin
2021
Completed Phase 2
~530

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,328 Previous Clinical Trials
14,874,595 Total Patients Enrolled
1 Trials studying Obsessive-Compulsive Disorder
30 Patients Enrolled for Obsessive-Compulsive Disorder
David B Yaden, PhDPrincipal InvestigatorJohns Hopkins University
1 Previous Clinical Trials
40 Total Patients Enrolled
Roland R Griffiths, PhDPrincipal InvestigatorJohns Hopkins University
3 Previous Clinical Trials
140 Total Patients Enrolled

Media Library

Psilocybin (Psychedelic) Clinical Trial Eligibility Overview. Trial Name: NCT05546658 — Phase < 1
Obsessive-Compulsive Disorder Research Study Groups: Immediate Psilocybin, Delayed Psilocybin
Obsessive-Compulsive Disorder Clinical Trial 2023: Psilocybin Highlights & Side Effects. Trial Name: NCT05546658 — Phase < 1
Psilocybin (Psychedelic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05546658 — Phase < 1
Obsessive-Compulsive Disorder Patient Testimony for trial: Trial Name: NCT05546658 — Phase < 1
~8 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top